[{"from": "human", "value": "Could you provide a description of this molecule? [C][C@H1][C][C@@H1][C@H1][Branch2][Ring1][=N][C][C][C@][Branch2][Ring1][=Branch1][C@H1][Ring1][=Branch1][C][C][C@@][Ring1][Branch1][Branch1][=Branch1][C][=Branch1][C][=O][C][O][C][=Branch1][C][=O][C][C][C@@][Branch1][=C][C][Ring2][Ring1][Branch1][=C][C][=Branch1][C][=O][C][C][Ring1][#Branch1][C]"}, {"from": "gpt", "value": "The molecule is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.  Medroxyprogesterone acetate was granted FDA approval on 18 June 1959."}]